Ticker LaunchDirect listing · PLYX
Polaryx Therapeutics, Inc.
Polaryx Therapeutics, Inc. (PLYX) went public through a direct listing on Nasdaq Capital Market on Feb 2, 2026.
Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric lysosomal storage disorders, using small molecule therapies, including a combination therapy, and a gene therapy.
- Status
- Direct listing
- Ticker
- PLYX
- Exchange
- Nasdaq Capital Market
- Listed
- Feb 2, 2026
- First filed
- Nov 21, 2025
- Sector
- Biotech & pharma
- Country / state
- NJ
More on this listing for subscribers
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Nov 21, 2025
- Latest amendment Jan 27, 2026
- Final prospectus (424B4) Feb 2, 2026
- All filings on EDGAR CIK 2075320
Other Biotech & pharma direct listings in 2026
- Lakewood-Amedex Biotherapeutics Inc.LABT · Apr 23, 2026